Abstract
Background
Although it is suggested that the endpoints originated from the concept of tumor shrinkage dynamics, such as early tumor shrinkage and depth of response, are strongly associated with overall survival (OS) in patients with metastatic colorectal cancer (mCRC), they are yet to be validated as a single surrogate endpoint of OS by themselves. This study aimed to investigate the impact of advantage in tumor response on the correlation between treatment effects on progression-free survival (PFS) and OS in mCRC patients.
Methods
Based on an electronic search, we identified randomized controlled trials of first-line therapy for mCRC. The impact of advantage in objective response rate (ORR) on the correlation between treatment effects on PFS and OS was evaluated based on Spearman correlation coefficients (rs).
Results
Forty-seven trials with a total of 24,018 patients were identified. The hazard ratio for PFS showed a relatively higher correlation with that for OS (rs = 0.63) when the trials were limited to those that demonstrated a larger difference in ORR, compared to the case for trials that demonstrated a smaller difference (rs = 0.32). This tendency was also observed in the subgroup analysis stratified by the types of treatment agents (targeted or non-targeted).
Conclusions
The magnitude of advantage in tumor response was suggested to contribute to a better prediction of OS benefit based on PFS in patients with mCRC. The accuracy of OS estimation in mCRC is expected to be improved by considering the degree of tumor shrinkage in conjunction with PFS.
Similar content being viewed by others
References
Food and Drug Administration (2018) Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. US department of health and human services. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics
Serugal B, Ocana A, Amir E et al (2015) Failures in phase III: causes and consequences. Clin Cancer Res 21(20):4552–4560. https://doi.org/10.1158/1078-0432.CCR-15-0124
Douaiher J, Ravipati A, Chowdhury S (2017) Colorectal cancer–global burden, trends, and geographical variations. J Surg Oncol 115:619–630. https://doi.org/10.1002/jso.24578
Schwartzberg LS, Rivera F, Karthaus M et al (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32(21):2240–2247. https://doi.org/10.1200/JCO.2013.53.2473
Stintzing S, Modest DP, Rossius L et al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17:1426–1434. https://doi.org/10.1016/S1470-2045(16)30269-8
Haslam A, Hey SP, Gill J et al (2019) A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. Eur J Cancer 106:196–211. https://doi.org/10.1016/j.ejca.2018.11.012
Piessevaux H, Buyse M, Schlichting M et al (2013) Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 31:3764–3775. https://doi.org/10.1200/JCO.2012.42.8532
Mansmann UR, Sartorius U, Laubender RP et al (2013) Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. J Clin Oncol 31(15). https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.3630
Cremolini C, Loupakis F, Antoniotti C et al (2015) Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26:1188–1194. https://doi.org/10.1093/annonc/mdv112
Douillard JY, Siena S, Peeters M et al (2015) Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 51:1231–1242. https://doi.org/10.1016/j.ejca.2015.03.026
Tsuji A, Sunakawa Y, Ichikawa W et al (2016) Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX Plus Cetuximab (JACCRO CC-05). Targ Oncol 11:799–806. https://doi.org/10.1007/s11523-016-0445-6
Petrelli F, Pietrantonio F, Cremolini C et al (2015) Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. Eur J Cancer 51(7):800–807. https://doi.org/10.1016/j.ejca.2015.02.011
Nakayama G, Fujii T, Murotani K et al (2016) Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer. Cancer Sci 107(10):1492–1498. https://doi.org/10.1111/cas.13023
Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784. https://doi.org/10.7326/M14-2385
Giessen C, Laubender RP, Ankerst DP et al (2013) Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res 19(1):225–235. https://doi.org/10.1158/1078-0432.CCR-12-1515
Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642–1649. https://doi.org/10.1093/jnci/djp369
Morita S, Sakamaki K, Yin G (2015) Detecting overall survival benefit derived from survival postprogression rather than progression-free survival. J Natl Cancer Inst 107:djv133. https://doi.org/10.1093/jnci/djv133
Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987–1992. https://doi.org/10.1200/JCO.2007.10.8407
Tang PA, Bentzen SM, Chen EX et al (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25(29):4562–4568. https://doi.org/10.1200/JCO.2006.08.1935
Aparicio T, Lavau-Denes S, Phelip JM et al (2016) Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Ann Oncol 27:121–127. https://doi.org/10.1093/annonc/mdv491
Passardi A, Nanni O, Tassinari D et al (2015) Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 26:1201–1207. https://doi.org/10.1093/annonc/mdv130
Brodowicz T, Ciuleanu TE, Radosavljevic D et al (2013) FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Ann Oncol 24:1769–1777. https://doi.org/10.1093/annonc/mdt116
Labianca R, Sobrero A, Isa L et al (2011) Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial. Ann Oncol 22:1236–1242. https://doi.org/10.1093/annonc/mdq580
Bokemeyer C, Bondarenko I, Hartmann JT et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:1535–1546. https://doi.org/10.1093/annonc/mdq632
Glimelius B, Sørbye H, Balteskard L et al (2008) A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 19(5):909–914. https://doi.org/10.1093/annonc/mdm588
Punt CJ, Keizer HJ, Douma J et al (2002) Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 13(1):81–86. https://doi.org/10.1093/annonc/mdf045
Blanke CD, Shultz J, Cox J et al (2002) A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol 13(1):87–91. https://doi.org/10.1093/annonc/mdf043
Kalofonos HP, Papakostas P, Makatsoris T et al (2010) Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. Anticancer Res 30(10): 4325–4333. https://ar.iiarjournals.org/content/30/10/4325.long
Souglakos J, Ziras N, Kakolyris S et al (2012) Randomised phase trial of CAPIRI capecitabine, irinotecan plus bevacizumab vs FOLFIRI folinic acid, 5fluorouracil, irinotecan plus bevacizumab as first-line treatment of patients with unresectablemetastatic colorectal cancer mCRC. Br J Cancer 106(3):453–459. https://doi.org/10.1038/bjc.2011.594
Yamazaki K, Kuwano H, Ojima H et al (2015) A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol 75(3):569–577. https://doi.org/10.1007/s00280-015-2676-0
Guan ZZ, Xu JM, Luo RC et al (2011) Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 30(10):682–689. https://doi.org/10.5732/cjc.011.10188
Cao B, Li ST, Li Z et al (2011) Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. Chin J Integr Med 17(8):593–599. https://doi.org/10.1007/s11655-011-0822-z
Tabernero J, Garcia-Carbonero R, Cassidy J et al (2013) Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res 19(9):2541–2550. https://doi.org/10.1158/1078-0432.CCR-13-0107
Douillard JY, Zemelka T, Fountzilas G et al (2014) FOLFOX4 with cetuximab vs UFOX with cetuximab as firstline therapy in metastatic colorectal cancer The randomized phase FUTURE study. Clin Colorectal Cancer 13(1):14–26.e1. https://doi.org/10.1016/j.clcc.2013.11.009
Gravalos C, Salut A, García-Girón C et al (2012) A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. Clin Transl Oncol 14(8):606–612. https://doi.org/10.1007/s12094-012-0843-x
Ducreux M, Bennouna J, Hebbar M et al (2011) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128(3):682–690. https://doi.org/10.1002/ijc.25369
Comella P, Massidda B, Filippelli G et al (2009) Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol 135(2):217–226. https://doi.org/10.1007/s00432-008-0454-7
Hoff PM, Hochhaus A, Pestalozzi BC et al (2012) Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30(29):3596–3603. https://doi.org/10.1200/JCO.2012.42.6031
Schmoll HJ, Cunningham D, Sobrero A et al (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30(29):3588–3595. https://doi.org/10.1200/JCO.2012.42.5355
Tveit KM, Guren T, Glimelius B et al (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 30(15):1755–1762. https://doi.org/10.1200/JCO.2011.38.0915
Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705. https://doi.org/10.1200/JCO.2009.27.4860
Tebbutt NC, Wilson K, Gebski VJ et al (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28(19):3191–3198. https://doi.org/10.1200/JCO.2009.27.7723
Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019. https://doi.org/10.1200/JCO.2007.14.9930
Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25(27):4217–4223. https://doi.org/10.1200/JCO.2006.09.2684
Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25(13):1670–1676. https://doi.org/10.1200/JCO.2006.09.0928
Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697–3705. https://doi.org/10.1200/JCO.2005.05.112
Köhne CH, van Cutsem E, Wils J et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: european organisation for research and treatment of cancer gastrointestinal group study 40986. J Clin Oncol 23(22):4856–4865. https://doi.org/10.1200/JCO.2005.05.546
Schilsky RL, Levin J, West WH et al (2002) Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 20(6):1519–1526. https://doi.org/10.1200/JCO.2002.20.6.1519
Seymour MT, Slevin ML, Kerr DJ et al (1996) Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 14(8):2280–2288. https://doi.org/10.1200/JCO.1996.14.8.2280
Venook AP, Niedzwiecki D, Lenz HJ et al (2017) Effect of first-line chemotherapy combined With Cetuximab or Bevacizumab on overall survival in patients with kras wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317(23):2392–2401. https://doi.org/10.1001/jama.2017.7105
Maughan TS, Adams RA, Smith CG et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783):2103–2114. https://doi.org/10.1016/S0140-6736(11)60613-2
Maughan TS, James RD, Kerr DJ et al (2002) Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359(9317):1555–1563. https://doi.org/10.1016/s0140-6736(02)08514-8
Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065–1075. https://doi.org/10.1016/S1470-2045(14)70330-4
Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17):1609–1618. https://doi.org/10.1056/NEJMoa1403108
Douillard JY, Oliner KS, Siena S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023–1034. https://doi.org/10.1056/NEJMoa1305275
Tol J, Koopman M, Cats A et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6):563–572. https://doi.org/10.1056/NEJMoa0808268
Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–1417. https://doi.org/10.1056/NEJMoa0805019
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. https://doi.org/10.1056/NEJMoa032691
Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905–914. https://doi.org/10.1056/NEJM200009283431302
Ocvirk J, Brodowicz T, Wrba F et al (2010) Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 16(25):3133–3143. https://doi.org/10.3748/wjg.v16.i25.3133
Cunningham D, Lang I, Marcuello E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14(11):1077–1085. https://doi.org/10.1016/S1470-2045(13)70154-2
Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30. https://doi.org/10.1200/JCO.2004.09.046
Yamazaki K, Nagase M, Tamagawa H et al (2016) Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 27(8):1539–1546. https://doi.org/10.1093/annonc/mdw206
García-Carbonero R, van Cutsem E, Rivera F et al (2017) Randomized phase II trial of Parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and Bevacizumab for first-line metastatic colorectal cancer. Oncologist 22(4):375–e30. https://doi.org/10.1634/theoncologist.2016-0133
Pinter T, Klippel Z, Cesas A et al (2017) A phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advanced or metastatic colorectal cancer: final results of the Pegfilgrastim and Anti-VEGF evaluation study (PAVES). Clin Colorectal Cancer 16(2):103–14. https://doi.org/10.1016/j.clcc.2016.08.008
Shi Q, De Gramont A, Grothey A et al (2015) Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol 33(1):22. https://doi.org/10.1200/JCO.2014.56.5887
Heinemann V, Stintzing S, Modest DP et al (2015) Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 51(14):1927–36. https://doi.org/10.1016/j.ejca.2015.06.116
Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–30. https://doi.org/10.1200/JCO.2013.53.0105
Daud A, Ribas A, Robert C et al (2015) Long-term efficacy of pembrolizumab pembro MK-3475 in a pooled analysis of 655 patients with advanced melanoma MEL enrolled in KEYNOTE001. ASCO Meet Abstr 33(15):9005. https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.9005
Acknowledgements
We would like to thank Kae Nakashima, Ph.D., for her support in English editing.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by YY and MK. The first draft of the manuscript was written by YY and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
All authors have no conflicts of interest that are directly relevant to this research. Yosuke Yoshida is an employee of MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Yoshida, Y., Kaneko, M. & Narukawa, M. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer. Int J Clin Oncol 25, 851–860 (2020). https://doi.org/10.1007/s10147-020-01619-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-020-01619-8